Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Release Date: December 18, 2025

Expiration Date: January 22, 2026

Activity Overview

Prostate-specific membrane antigen (PSMA)–targeted imaging and radioligand therapies are rapidly transforming the treatment landscape for advanced prostate cancer, especially metastatic castration-resistant prostate cancer. Despite recent FDA approvals and promising data, community oncologists face persistent challenges incorporating these innovations into practice, including patient selection, sequencing of therapies, management of adverse events, and disparities in access to PSMA diagnostics and treatments.

To address these needs, this CME-certified initiative pairs a national PSMA expert with a local community oncologist to facilitate practical, case-based discussions and equip learners with actionable strategies for integrating PSMA-targeted approaches into real-world care.

This educational activity is an archive of the Community Oncology Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies presentation held on December 5, 2025.

Target Audience

This educational program is primarily directed toward community-based oncologists, radiation oncologists, nuclear medicine physicians, advanced practice providers, and other health care professionals involved in the treatment of prostate cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate the diagnostic and prognostic significance of PSMA PET imaging in advanced prostate cancer and integrate imaging findings into systemic treatment decisions
• Assess recent clinical trial evidence supporting PSMA-targeted radioligand therapies and determine patient eligibility and optimal timing for initiation within community oncology practice
• Implement patient-centered strategies for managing PSMA-directed radioligand therapy, including effective sequencing with androgen receptor signaling inhibitors (ARSIs), chemotherapy, and novel combination therapies
• Identify practical barriers to accessing and delivering PSMA-directed imaging and radioligand therapy in community practice settings and develop collaborative solutions to expand equitable patient access